Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The objective of this study was to investigate the risk of attenuated efficacy due to adaptive resistance for the siderophore-conjugated monocarbam SMC-3176 in Pseudomonas aeruginosa by using a pharmacokinetic/pharmacodynamic (PK/PD) approach. MICs were determined in cation-adjusted Mueller-Hinton broth (MHB) and in Chelex-treated, dialyzed MHB (CDMHB). Spontaneous resistance was assessed at 2× to 16× the MIC and the resulting mutants sequenced. Efficacy was evaluated in a neutropenic mouse thigh model at 3.13 to 400 mg/kg of body weight every 3 h for 24 h and analyzed for association with free time above the MIC ( fT >MIC). To closer emulate the conditions of the in vivo model, we developed a novel assay testing activity mouse whole blood (WB). All mutations were found in genes related to iron uptake: piuA , piuC , pirR , fecI , and pvdS . Against four P. aeruginosa isolates, SMC-3176 displayed predictable efficacy corresponding to the fT >MIC using the MIC in CDMHB ( R 2 = 0.968 to 0.985), with stasis to 2-log kill achieved at 59.4 to 81.1%. Efficacy did not translate for P. aeruginosa isolate JJ 4-36, as the in vivo responses were inconsistent with fT >MIC exposures and implied a threshold concentration that was greater than the MIC. The results of the mouse WB assay indicated that efficacy was not predictable using the MIC for JJ 4-36 and four additional isolates, against which in vivo failures of another siderophore-conjugated β-lactam were previously reported. SMC-3176 carries a risk of attenuated efficacy in P. aeruginosa due to rapid adaptive resistance preventing entry via the siderophore-mediated iron uptake systems. Substantial in vivo testing is warranted for compounds using the siderophore approach to thoroughly screen for this in vitro-in vivo disconnect in P. aeruginosa .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 3×
“The PK/PD index for SMC3176 was reasonably assumed to be time driven (supported by in vitro time-kill results for SMC-3176 [data not shown]), as this has been well-established for various drug classes belonging to the -lactam family (12, 24), and greater emphasis was placed on exploring the potential loss of in vivo e…”
BackgroundResultInfluentialSiderophore-Based Iron Acquisition and Pathogen Control
Miethke, M., & Marahiel, M. A. (2007) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00012-07 · Cited by 1,774 · cited 6×
“TABLE 3 Characterization and susceptibilities of mutants generated from in vitro spontaneous resistance studies for SMC-3176 in P. aeruginosa Parent/mutant (selection concn [ MIC]) Mutationa MIC in MHB (mg/liter) SMC-3176 MB-1 MC-8 Aztreonam Ceftazidime Meropenem PAO1 0.25 0.5 0.5 4 2 1 A1-PAO1 (4) [PiuC(PA4515). . .P…”
BackgroundInfluentialAdaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa
Tomaras, A. P., Crandon, J. L., McPherson, C. J., Banevicius, M. A., Finegan, S. M., Irvine, R. L., Brown, M. F., O'Donnell, J. P., & Nicolau, D. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00629-13 · Cited by 110
Self-citationMcPherson, C. J., Aschenbrenner, L. M., Lacey, B. M., Fahnoe, K. C., Lemmon, M. M., Finegan, S. M., Tadakamalla, B., O'Donnell, J. P., Mueller, J. P., & Tomaras, A. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01345-12 · Cited by 91
Tomaras, A. P., Crandon, J. L., McPherson, C. J., & Nicolau, D. P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04172-14 · Cited by 32 · cited 1×
“activity of the siderophore conjugate is a consideration (36, 37).”
BackgroundSelf-citation
Cited by
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Ito, A., Sato, T., Ota, M., Takemura, M., Nishikawa, T., Toba, S., Kohira, N., Miyagawa, S., Ishibashi, N., Matsumoto, S., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01454-17 · Cited by 400
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Sato, T., & Yamawaki, K. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz826 · Cited by 379
Ito, A., Nishikawa, T., Matsumoto, S., Yoshizawa, H., Sato, T., Nakamura, R., Tsuji, M., & Yamano, Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01405-16 · Cited by 352
Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?
Domalaon, R., Idowu, T., Zhanel, G. G., & Schweizer, F. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00077-17 · Cited by 285
Metadata
- Authors
- Kim, A., Kutschke, A., Ehmann, D. E., Patey, S. A., Crandon, J. L., Gorseth, E., Miller, A. A., McLaughlin, R. E., Blinn, C. M., Chen, A., Nayar, A. S., Dangel, B., Tsai, A. S., Rooney, M. T., Murphy-Benenato, K. E., Eakin, A. E., & Nicolau, D. P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-12
- Volume
- 59
- Issue
- 12
- Pages
- 7743-7752
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2198013734
- Cited by
- 79
- References
- 5
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy. https://app.cochat.ai/papers/10.1128/aac.00831-15
- The paper
- Kim, A., Kutschke, A., Ehmann, D. E., Patey, S. A., Crandon, J. L., Gorseth, E., Miller, A. A., McLaughlin, R. E., Blinn, C. M., Chen, A., Nayar, A. S., Dangel, B., Tsai, A. S., Rooney, M. T., Murphy-Benenato, K. E., Eakin, A. E., & Nicolau, D. P. (2015). Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00831-15
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.